Pleural Cancer disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: PLR006 MIFTS: 41	Pleural Cancer Categories: Cancer diseases
Genes Tissues Related diseases Publications Drugs Download Expand all tables

Sources

Aliases & Classifications for Pleural Cancer

MalaCards integrated aliases for Pleural Cancer:

Name: Pleural Cancer ¹² ¹⁵

Pleural Neoplasms ⁴⁴ ⁷³

Malignant Tumor of Pleura ⁷³

Neoplasm of Pleura ¹²

Pleural Tumor ¹²

Classifications:

MalaCards categories:
Global: Cancer diseases

See all MalaCards categories (disease lists)

ICD10: ³³

Neoplasms

Malignant neoplasms of respiratory and intrathoracic organs

Malignant neoplasm of heart, mediastinum and pleura

Malignant neoplasm: Pleura

External Ids:

Disease Ontology ¹² DOID:5158

ICD10 ³³ C38.4

ICD9CM ³⁵ 163 163.9

MeSH ⁴⁴ D010997

NCIt ⁵⁰ C3332 C3547

SNOMED-CT ⁶⁸ 126719004 187880003 363433009 more

UMLS ⁷³ C0032229 C0153494

Sources

Summaries for Pleural Cancer

Disease Ontology : ¹² A connective tissue cancer that located in the pleura.

MalaCards based summary : Pleural Cancer, also known as pleural neoplasms, is related to malignant pleural mesothelioma and pleural disease. An important gene associated with Pleural Cancer is BAP1 (BRCA1 Associated Protein 1). The drugs Alimta and Zoledronic acid have been mentioned in the context of this disorder. Affiliated tissues include the pleura, lung and testes, and related phenotypes are behavior/neurological and mortality/aging

Sources

Related Diseases for Pleural Cancer

Diseases related to Pleural Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 65)

#	Related Disease	Score	Top Affiliating Genes
1	malignant pleural mesothelioma	29.2	BAP1 CALB2 EFEMP1 MSLN SPP1 TYMS
2	pleural disease	11.1
3	corpus luteum cyst	10.9	MUC16 SMUG1
4	heart cancer	10.8	MUC16 SMUG1
5	malignant spiradenoma	10.7	KRT5 SMUG1
6	scrotal carcinoma	10.7	CDKN2A SMUG1
7	inverted transitional papilloma	10.7	CDKN2A KRT5
8	keratinizing squamous cell carcinoma	10.7	CDKN2A KRT5
9	atypical neurofibroma	10.6	CDKN2A NF2
10	fallopian tube squamous cell carcinoma	10.6	CDKN2A WT1
11	anal canal squamous cell carcinoma	10.6	CDKN2A KRT5
12	schneiderian carcinoma	10.6	CDKN2A KRT5
13	pseudo-meigs syndrome	10.6	CALB2 MUC16
14	melanomatosis	10.5	CDKN2A WT1
15	oropharynx cancer	10.5	CDKN2A SMUG1
16	malignant peritoneal mesothelioma	10.5	BAP1 CDKN2A NF2
17	sarcomatoid mesothelioma	10.5	CDKN2A WT1
18	adenofibroma	10.5	CALB2 MUC16
19	cervical clear cell adenocarcinoma	10.5	CDKN2A KRT5
20	fallopian tube endometrioid adenocarcinoma	10.5	CALB2 CDKN2A
21	heart sarcoma	10.5	SMUG1 WT1
22	prostate squamous cell carcinoma	10.4	KRT5 SMUG1
23	anus cancer	10.4	CDKN2A KRT5 SMUG1
24	breast giant fibroadenoma	10.4	CDKN2A WT1
25	lymphohistiocytoid mesothelioma	10.4	CALB2 CDKN2A
26	mucinous bronchioloalveolar adenocarcinoma	10.4	CALB2 CDKN2A
27	tuberculous peritonitis	10.4	MUC16 SMUG1
28	optic nerve sheath meningioma	10.4	CDKN2A KRT5 NF2
29	gastrointestinal system cancer	10.4	CDKN2A SMUG1 TYMS
30	optic nerve neoplasm	10.4	CDKN2A KRT5 NF2
31	respiratory system cancer	10.4	CD274 CDKN2A SMUG1
32	lymphoepithelioma-like carcinoma	10.4	CD274 KRT5
33	fallopian tube carcinosarcoma	10.3	CALB2 WT1
34	peritoneum cancer	10.3	BAP1 KRT5 WT1
35	nasal cavity squamous cell carcinoma	10.3	CDKN2A KRT5
36	pancreas adenocarcinoma	10.3	CDKN2A MSLN MUC16
37	venous hemangioma	10.2	CALB2 WT1
38	papilloma	10.2	CDKN2A KRT5 TYMS
39	spindle cell liposarcoma	10.2	CALB2 WT1
40	sertoli-leydig cell tumor	10.2	CALB2 WT1
41	thymus cancer	10.1	CALB2 KRT5 SMUG1
42	sertoli cell tumor	10.1	CALB2 WT1
43	adenomatoid tumor	10.1	CALB2 MUC16 WT1
44	ovarian brenner tumor	10.1	CALB2 MUC16 WT1
45	female reproductive organ cancer	10.1	CDKN2A MSLN MUC16 SMUG1
46	peritoneal mesothelioma	10.0	BAP1 CDKN2A NF2 WT1
47	cell type cancer	10.0	CD274 CDKN2A KRT5 SMUG1
48	pericardium cancer	10.0	CALB2 MSLN SMUG1
49	pneumatosis cystoides intestinalis	10.0	CALB2 WT1
50	necrotizing sialometaplasia	9.9	CDKN2A KRT5

Comorbidity relations with Pleural Cancer via Phenotypic Disease Network (PDN):

Deficiency Anemia

Graphical network of the top 20 diseases related to Pleural Cancer:

Sources

Symptoms & Phenotypes for Pleural Cancer

MGI Mouse Phenotypes related to Pleural Cancer:

⁴⁶

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	behavior/neurological	MP:0005386	9.97	NF2 NGB SPP1 ASS1 CALB2 CD274
2	mortality/aging	MP:0010768	9.9	ASS1 BAP1 CD274 CDKN2A EFEMP1 KRT5
3	integument	MP:0010771	9.86	CDKN2A EFEMP1 KRT5 NF2 SPP1 ASS1
4	neoplasm	MP:0002006	9.43	BAP1 CDKN2A NF2 SMUG1 SPP1 WT1
5	no phenotypic analysis	MP:0003012	9.1	BAP1 CD274 CDKN2A KRT5 NGB WT1

Sources

Drugs & Therapeutics for Pleural Cancer

FDA approved drugs:

#	Drug Name	Active Ingredient(s) ¹⁸	Company	Approval Date
1	Alimta ¹⁸ ⁴⁹	PEMETREXED (also Pemetrexed Disodium)	Eli Lilly	February 2004
FDA Label: Alimta Disease/s that Drug Treats:Mesothelioma Indications and Usage: ¹⁸ ALIMTAÂ® is a folate analog metabolic inhibitor indicated for: Locally Advanced or Metastatic Nonsquamous Non-Small CellLung Cancer: Initial treatment in combination with cisplatin. (1.1) Maintenance treatment of patients whose disease has notprogressed after four cycles of platinum-based first-linechemotherapy. (1.2) After prior chemotherapy as a single-agent. (1.3) Mesothelioma: in combination with cisplatin. (1.4)Limitations of Use: ALIMTA is not indicated for the treatment of patients withsquamous cell non-small cell lung cancer. (1.5) DrugBank Targets: ¹⁶ 1. Thymidylate synthase;2. Bifunctional purine biosynthesis protein PURH;3. Dihydrofolate reductase;4. Trifunctional purine biosynthetic protein adenosine-3 Mechanism of Action: ¹⁸ Target: folic acid/ thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase Action: antagonist/ inhibitor FDA: ALIMTA, pemetrexed for injection, is a folate analog metabolic inhibitor that exerts its action by disrupting folatedependentmetabolic processes essential for cell replication. In vitro studies have shown that pemetrexed inhibitsthymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT),which are folate-dependent enzymes involved in the de novo biosynthesis of thymidine and purine nucleotides.Pemetrexed is taken into cells by membrane carriers such as the reduced folate carrier and membrane folate bindingprotein transport systems. Once in the cell, pemetrexed is converted to polyglutamate forms by the enzymefolylpolyglutamate synthetase. The polyglutamate forms are retained in cells and are inhibitors of TS and GARFT.Polyglutamation is a time- and concentration-dependent process that occurs in tumor cells and, is thought to occur to alesser extent, in normal tissues. Polyglutamated metabolites are thought to have an increased intracellular half-liferesulting in prolonged drug action in malignant cells.

Drugs for Pleural Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 141)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Zoledronic acid

Approved

Phase 4,Phase 2

118072-93-8

68740

Iodine

Approved, Investigational

Phase 4,Phase 3,Not Applicable

7553-56-2

807

Povidone-iodine

Approved

Phase 4,Phase 3

25655-41-8

Povidone

Approved

Phase 4,Phase 3

9003-39-8

Pharmaceutical Solutions

Phase 4,Phase 3,Phase 2,Not Applicable

Anti-Infective Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Anti-Infective Agents, Local

Phase 4,Phase 3,Phase 2

Micronutrients

Phase 4,Phase 1

Trace Elements

Phase 4,Phase 1

Diphosphonates

Phase 4,Phase 2

Bone Density Conservation Agents

Phase 4,Phase 2

cadexomer iodine

Phase 4,Phase 3,Not Applicable

Plasma Substitutes

Phase 4,Phase 3

Blood Substitutes

Phase 4,Phase 3

Cisplatin

Approved

Phase 3,Phase 2,Phase 1,Not Applicable

15663-27-1

84093 441203 2767

Bevacizumab

Approved, Investigational

Phase 3,Phase 2,Phase 1

216974-75-3

Doxycycline

Approved, Investigational, Vet_approved

Phase 3,Phase 2,Not Applicable

564-25-0

54671203

Bleomycin

Approved, Investigational

Phase 3

11056-06-7

5360373

Angiogenesis Inhibitors

Phase 3,Phase 2,Phase 1

Angiogenesis Modulating Agents

Phase 3,Phase 2,Phase 1

Viscum album peptide

Phase 3

Anti-Bacterial Agents

Phase 3,Phase 2,Not Applicable

Antibiotics, Antitubercular

Phase 3

Anti-HIV Agents

Phase 3

Antiparasitic Agents

Phase 3,Phase 2,Not Applicable

Antiprotozoal Agents

Phase 3,Phase 2,Not Applicable

Anti-Retroviral Agents

Phase 3

Antimalarials

Phase 3,Phase 2,Not Applicable

Antiviral Agents

Phase 3,Phase 2,Phase 1

European Mistletoe

Nutraceutical

Phase 3

silver nitrate

Approved, Investigational

Phase 2

Morphine

Approved, Investigational

Phase 2,Not Applicable

57-27-2

5288826

Ibuprofen

Approved

Phase 2,Not Applicable

15687-27-1

3672

Gemcitabine

Approved

Phase 2,Phase 1

95058-81-4

60750

Carboplatin

Approved

Phase 2,Phase 1

41575-94-4

10339178 498142 38904

Paclitaxel

Approved, Vet_approved

Phase 2,Phase 1

33069-62-4

36314

Cetuximab

Approved

Phase 2

205923-56-4

56842117 2333

Bortezomib

Approved, Investigational

Phase 2,Phase 1

179324-69-7

387447 93860

Gefitinib

Approved, Investigational

Phase 2

184475-35-2

123631

Docetaxel

Approved, Investigational

Phase 2,Phase 1

114977-28-5

148124

Vinorelbine

Approved, Investigational

Phase 2

71486-22-1

60780 44424639

Pemetrexed

Approved, Investigational

Phase 2

150399-23-8, 137281-23-3

446556 60843

Metformin

Approved

Phase 2

657-24-9

14219 4091

Methotrexate

Approved

Phase 2

1959-05-2, 59-05-2

126941

Naproxen

Approved, Vet_approved

Phase 2

22204-53-1

1302 156391

Pantoprazole

Approved

Phase 2

102625-70-7

4679

leucovorin

Approved, Nutraceutical

Phase 2

58-05-9

143 6006

Folic Acid

Approved, Nutraceutical, Vet_approved

Phase 2,Phase 1

59-30-3

6037

Cediranib

Investigational

Phase 2

288383-20-0

9933475

Saracatinib

Investigational

Phase 2

379231-04-6

Interventional clinical trials:

(show top 50) (show all 99)

#	Name	Status	NCT ID	Phase	Drugs
1	Safety Profile of Iodopovidone as an Agent for Pleurodesis in Malignant Pleural Effusion	Completed	NCT01670786	Phase 4
2	Impact of Aggressive Versus Standard Drainage Regimen Using a Long Term Indwelling Pleural Catheter	Completed	NCT00978939	Phase 4
3	Talc Pleurodesis in Patients With Recurrent Malignant Pleural Effusion	Completed	NCT00789087	Phase 4
4	Non-small Cell Lung Cancer Registry	Completed	NCT00099541	Phase 4	zoledronic acid
5	Betadine Pleurodesis Via Tunneled Pleural Catheters	Not yet recruiting	NCT02975921	Phase 4	Povidone-Iodine
6	Safety, Efficacy, and Side Effects Study of Interventional Cryotherapy in the Pleural Space("ICE PLS")	Terminated	NCT00747916	Phase 4
7	Indwelling Pleural Catheter for Trapped Lung	Completed	NCT03550027	Phase 3
8	Efficacy and Safety Study of Abnoba Viscum F 20mg in Malignant Pleural Effusion Patients	Completed	NCT02191540	Phase 3	Abnoba Viscum F 20mg
9	A Prospective, Randomized Controlled Trial for a Rapid Pleurodesis Protocol for the Management of Pleural Effusions	Completed	NCT00758316	Phase 3
10	Intrapleural Bevacizumab and Cisplatin Therapy for Malignant Pleural Effusion Caused by Non-small Cell Lung Cancer	Completed	NCT01661790	Phase 3	Bevacizumab;Cisplatin
11	Bleomycin, Doxycycline, or Talc in Treating Patients With Malignant Pleural Effusions	Completed	NCT00002872	Phase 3	doxycycline
12	Talc in Treating Patients With Malignant Pleural Effusion	Completed	NCT00002622	Phase 3	talc;Talc
13	Standard Chest Tube Compared With a Small Catheter in Treating Malignant Pleural Effusion in Patients With Cancer	Completed	NCT00042770	Phase 3
14	Efficacy of Iodopovidone Versus Talc in Palliative Malignant Pleural Effusion	Recruiting	NCT02674243	Phase 3	Iodopovidone solution;Talc
15	A Study to Compare the Efficacy and Safety of Intrapleural Doxycycline Versus Iodopovidone for Performing Pleurodesis in Malignant Pleural Effusion	Recruiting	NCT02583282	Phase 3
16	Recombinant Adenoviral Human p53 Gene in Treatment of Malignant Pleural Effusion	Unknown status	NCT02429726	Phase 2	rAdp53;Cisplatin;rAdp53 plus cisplatin
17	Efficacy and Safety of Bevacizumab Versus Pulvis Talci in Malignant Pleural Effusion	Unknown status	NCT02054078	Phase 2	Bevacizumab;Pulvis talci
18	Safety and Effectiveness Study for Pleurodesis With Silver Nitrate in Malignant Pleural Effusion	Unknown status	NCT01125124	Phase 2	Silver Nitrate
19	Safety and Effectiveness Study of Tumor Cell-derived Microparticles to Treat Malignant Ascites and Pleural Effusion	Unknown status	NCT01854866	Phase 2
20	Ibuprofen or Morphine in Treating Pain in Patients Undergoing Pleurodesis for Malignant Pleural Effusion	Unknown status	NCT00644319	Phase 2	ibuprofen;morphine sulfate
21	Phase II Trial of Neo-Adjuvant Pemetrexed Plus Cisplatin Followed by Surgery and Radiation for Pleural Mesothelioma	Completed	NCT00087698	Phase 2	pemetrexed;cisplatin
22	S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery	Completed	NCT00243074	Phase 2	cediranib maleate
23	Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases	Completed	NCT00154388	Phase 2	Imatinib mesylate
24	Tunneled Pleural Catheter in Partially Entrapped Lung	Completed	NCT00637676	Phase 2
25	Endostar and/or Cisplatin for Treatment of Malignant Pleural Effusion or Ascites	Completed	NCT01327235	Phase 2	Endostar;Cisplatin
26	FDG-Labeled PET Scan in Planning Chemotherapy in Treating Patients With Stage IIIB or IV Non-Small Cell Lung Cancer	Completed	NCT00564733	Phase 2	carboplatin;docetaxel;gemcitabine hydrochloride;paclitaxel
27	AZD0530 in Treating Patients With Extensive Stage Small Cell Lung Cancer	Completed	NCT00528645	Phase 2	saracatinib
28	Imatinib Mesylate and Paclitaxel in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer	Completed	NCT00408460	Phase 2	imatinib mesylate;paclitaxel
29	Phase II Study of Docetaxel + ZD1839 in Elderly Patients With Non-Small Cell Lung Cancer	Completed	NCT00231465	Phase 2	docetaxel (Taxotere®);ZD1839
30	The 'MADe IT' Clinical Trial: Molecular Analyses Directed Individualized Therapy for Advanced Non-Small Cell Lung Cancer	Completed	NCT00215930	Phase 2	Vinorelbine;Docetaxel;Gemcitabine;Carboplatin
31	Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer	Completed	NCT00118183	Phase 2	docetaxel;bortezomib
32	Intrapleural Docetaxel Administration Using Medical Pleuroscopy in Malignant Effusion With Lung Cancer	Recruiting	NCT03394105	Phase 2	intrapleural docetaxel administration
33	Clinical Trial of Tumor Cell-derived Microparticles Packaging Chemotherapeutic Drugs to Treat Malignant Pleural Effusion	Recruiting	NCT02657460	Phase 2	cisplatin
34	Effectiveness of Doxycycline for Treating Pleural Effusions Related to Cancer in an Outpatient Population	Recruiting	NCT01411202	Phase 2	Doxycycline
35	Bevacizumab in the Treatment of Malignant Pleural Effusions of Non-squamous Non-small Cell Lung Cancer	Recruiting	NCT02942043	Phase 2	Bevacizumab
36	Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Recruiting	NCT02122185	Phase 2	metformin hydrochloride;placebo;Chemotherapy
37	Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung Cancer	Active, not recruiting	NCT00126581	Phase 2	Carboplatin;Erlotinib Hydrochloride;Paclitaxel
38	Intrapleural Bevacizumab Injection for Malignant Effusion in Lung Cancer	Enrolling by invitation	NCT02054052	Phase 2	Bevacizumab
39	The Effect of Non-Steroidal Anti-Inflammatory Drug Naproxen on Pleural Effusion Formation After Lung Resection	Terminated	NCT01612975	Phase 2	Naproxen;Placebo
40	Cediranib as Palliative Treatment in Patients With Symptomatic Malignant Ascites or Pleural Effusion	Terminated	NCT01262612	Phase 2	immediate cediranib;Start cediranib after 28 days Best Supportive Care
41	Zometa Adjuvant Treatment of Malignant Pleural Effusion Due To Non-Small Cell Lung Cancer	Terminated	NCT01004510	Phase 2	zoledronic acid
42	Malignant Pleural Effusion With ZD6474	Terminated	NCT00402896	Phase 2	ZD6474
43	Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions	Unknown status	NCT00066404	Phase 1
44	BAY 43-9006 in Previously Untreated Patients With Non-Small Cell Lung Cancer (NSCLC)	Completed	NCT00533585	Phase 1	BAY 43-9006;Paclitaxel;Carboplatin;Bevacizumab
45	Surgery and Intrapleural Docetaxel in Treating Patients With Malignant Pleural Effusion	Completed	NCT00114205	Phase 1	docetaxel
46	Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu	Completed	NCT00004074	Phase 1
47	Bortezomib Plus Gemcitabine and Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer	Completed	NCT00052338	Phase 1	gemcitabine hydrochloride;carboplatin;bortezomib
48	Photo-induction as a Means to Improve Cisplatin Delivery to Pleural Malignancies	Recruiting	NCT02702700	Phase 1	Cisplatin, liposomal;Verteporfin
49	Combination Tissue Plasminogen Activator (Tpa) and Dornase Alfa (Dnase) Administration Through Intrapleural Catheters for the Treatment of Loculated or Non-Draining Malignant Pleural Effusions	Recruiting	NCT02135588	Phase 1	Combination TISSUE PLASMINOGEN ACTIVATOR (TPA) AND DORNASE ALFA (DNASE)
50	Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)	Active, not recruiting	NCT01999985	Phase 1	Dasatinib - 1A;Afatinib - 1A;Dasatinib - 1B;Afatinib - 1B

Search NIH Clinical Center for Pleural Cancer

Cochrane evidence based reviews: pleural neoplasms

Sources

Genetic Tests for Pleural Cancer

Sources

Anatomical Context for Pleural Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Pleural Cancer:

¹⁹

The Pleura

MalaCards organs/tissues related to Pleural Cancer:

⁴¹

Lung, Testes, Prostate, Endothelial, Bone, Liver

Sources

Publications for Pleural Cancer

Articles related to Pleural Cancer:

(show all 20)

#	Title	Authors	Year
1	Survival patterns in lung and pleural cancer in Europe 1999-2007: Results from the EUROCARE-5 study. ( 26421826 )	Francisci S....Sant M.	2015
2	A microfluidic platform for chemoresistive testing of multicellular pleural cancer spheroids. ( 24496222 )	Ruppen J....Guenat O.T.	2014
3	Pleural cancer mortality in Spain: time-trends and updating of predictions up to 2020. ( 24195451 )	LA^pez-Abente G....Pastor-Barriuso R.	2013
4	Pleural cancer antigen-125 levels in benign and malignant pleural effusions. ( 23575338 )	Choi W.I....Kwon K.Y.	2013
5	Industrial pollution and pleural cancer mortality in Spain. ( 22444064 )	LA^pez-Abente G....GarcA-a-PAcrez J.	2012
6	Systematic evaluation of three different commercial software solutions for automatic segmentation for adaptive therapy in head-and-neck, prostate and pleural cancer. ( 22989046 )	La Macchia M....Widesott L.	2012
7	Value of D2-40 in the differential diagnosis of pleural neoplasms with emphasis on its positivity in solitary fibrous tumor. ( 20436345 )	Hu Y....Xu H.	2010
8	Development of a rabbit pleural cancer model by using VX2 tumors. ( 18589872 )	Kreuter K.A....Brenner M.	2008
9	Minimally invasive localization of oncolytic herpes simplex viral therapy of metastatic pleural cancer. ( 16037824 )	Stiles B.M....Fong Y.	2006
10	Municipal pleural cancer mortality in Spain. ( 15723885 )	LA^pez-Abente G....PAcrez-GA^mez B.	2005
11	Three decades of pleural cancer and mesothelioma registration in Austria where asbestos cement was invented. ( 12733090 )	Neuberger M....Vutuc C.	2003
12	Replication-competent herpes virus NV1020 as direct treatment of pleural cancer in a rat model. ( 12091817 )	Ebright M.I....Fong Y.	2002
13	Exposure to asbestos and lung and pleural cancer mortality among pulp and paper industry workers. ( 12085486 )	Carel R....Kogevinas M.	2002
14	Is the ratio of pleural mesothelioma mortality to pleural cancer mortality approximately unity for Italy? Considerations from the oldest regional mesothelioma register in Italy. ( 12085195 )	Gorini G....Costantini A.S.	2002
15	Prognostic implication of Ki-67 immunostaining in treating subclinical pleural cancer found at thoracotomy in lung cancer patients. ( 11426745 )	Shiba M....Fujisawa T.	2001
16	An age, period and cohort analysis of pleural cancer mortality in Europe. ( 10954257 )	La Vecchia C....Negri E.	2000
17	Differences in occupational mortality from pleural cancer, peritoneal cancer, and asbestosis. ( 8535500 )	Coggon D....Pannett B.	1995
18	Metastatic pleural cancer in radionuclide angiocardiography. A pulmonary time-activity curve mimicking left-to-right cardiac shunt. ( 8565354 )	Lee J....Lee K.	1995
19	&quot;Patient-like&quot; nude mouse metastatic model of advanced human pleural cancer. ( 7806595 )	Astoul P....Hoffman R.M.	1994
20	Patient-like nude-mouse and scid-mouse models of human lung and pleural cancer (review). ( 21573423 )	Astoul P....Hoffman R.	1993

Sources

Genes for Pleural Cancer

Genes related to Pleural Cancer (0 elite genes):

(show all 17)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	BAP1	BRCA1 Associated Protein 1	Protein Coding	16.46	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
2	MUC16	Mucin 16, Cell Surface Associated	Protein Coding	16.32	GeneCards inferred via : Publications (show sections)
3	EFEMP1	EGF Containing Fibulin Extracellular Matrix Protein 1	Protein Coding	16.24	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
4	SMUG1	Single-Strand-Selective Monofunctional Uracil-DNA Glycosylase 1	Protein Coding	15.95	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
5	SPP1	Secreted Phosphoprotein 1	Protein Coding	15.83	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
6	ASS1	Argininosuccinate Synthase 1	Protein Coding	15.66	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
7	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	15.48	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
8	NF2	Neurofibromin 2	Protein Coding	15.42	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
9	KRT5	Keratin 5	Protein Coding	15.39	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
10	TYMS	Thymidylate Synthetase	Protein Coding	15.38	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
11	CD274	CD274 Molecule	Protein Coding	15.29	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
12	WT1	Wilms Tumor 1	Protein Coding	15.26	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
13	MSLN	Mesothelin	Protein Coding	8.36	DISEASES inferred ¹⁵
14	CALB2	Calbindin 2	Protein Coding	6.96	DISEASES inferred ¹⁵
15	MIR611	MicroRNA 611	RNA Gene	5.62	DISEASES inferred ¹⁵
16	KAZALD1	Kazal Type Serine Peptidase Inhibitor Domain 1	Protein Coding	5.53	DISEASES inferred ¹⁵
17	NGB	Neuroglobin	Protein Coding	5.45	DISEASES inferred ¹⁵

Sources

Variations for Pleural Cancer

Sources

Expression for Pleural Cancer

Search GEO for disease gene expression data for Pleural Cancer.

Sources

Pathways for Pleural Cancer

Sources

GO Terms for Pleural Cancer

Biological processes related to Pleural Cancer according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	negative regulation of cell proliferation	GO:0008285	9.46	BAP1 CDKN2A NF2 WT1
2	negative regulation of cell-matrix adhesion	GO:0001953	8.96	CDKN2A NF2
3	diaphragm development	GO:0060539	8.62	ASS1 WT1

Sources

Sources for Pleural Cancer

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ ExPASy

¹⁸ FDA Approved Drugs

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ SNOMED-CT via Orphanet

⁷¹ TGDB

⁷² Tocris

⁷³ UMLS

⁷⁴ UMLS via Orphanet

⁷⁵ UniProtKB/Swiss-Prot

⁷⁶ Wikipedia